- Robust total revenue of US$88.2 million, representing 98% year-on-year growth
- Terumo Corporation (“Terumo”), Biosensors’ licensing partner, continued strong momentum in the sales of its Nobori drug-eluting stent (“DES”), resulting in a 378% year-on-year increase in Biosensors’ licensing and royalties revenue to US$22.8 million
- Net profit excluding exceptional items increased 72% year-on-year to US$28.6 million
- Generated operating cash flow of US$32.4 million in Q4 FY12, a 143% increase from a year ago
- Total revenue of US$292.1 million, an 87% growth, exceeding the Company’s financial guidance of 70% – 80% year-on-year growth
- Terumo’s strong revenue growth for its Nobori DES contributed to a 370% year-on-year increase in Biosensors’ total licensing revenue to US$80.8 million in FY12
- FY12 net profit excluding exceptional items increased 92% year-on-year to US$101 million
- Generated operating cash flow of US$81.0 million in FY12, a 192% increase from a year ago
- Successfully consolidated JW Medical Systems Ltd. (“JWMS”) in early October 2011 and included its half-year financial results
Posts
No comments:
Post a Comment